Laxatives or anti-diarrheals

PreclinicalSmall molecule

UUniversity of North Carolina, Chapel Hill

Laxatives or anti-diarrheals is one of 6 small molecule programs targeting Fecal Incontinence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fecal IncontinenceActive, not recruiting

Fecal IncontinencePreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Fecal Incontinence

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

—2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Iltamiocel

2 4

Botulinum Toxin a

GSK

Phase 1

1 5

Polyethylene Glycols

JJinnah Postgraduate Medical Centre

Preclinical

1 6

Laxatives or anti-diarrheals

UUniversity of North Carolina, Chapel Hill

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fecal Incontinence1 trial

Educational-Medical-Behavioral Treatment of Fecal Incontinence

Terminated·UUniversity of North Carolina, Chapel Hill·N/A·NCT01717456·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Laxatives or anti-diarrheals. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Laxatives or anti-diarrheals compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Laxatives or anti-diarrheals. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of North Carolina, Chapel Hill

Laxatives or anti-diarrheals

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fecal Incontinence1 trial

References

Drug Info

Quick Facts

Related News